Metastatic Colorectal Cancer Clinical Trials

136 recruitingLast updated: June 17, 2026

There are 136 actively recruiting metastatic colorectal cancer clinical trials across 47 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, Shanghai, Shanghai Municipality, China, Barcelona, Spain. Updated daily from ClinicalTrials.gov.


Metastatic Colorectal Cancer Trials at a Glance

136 actively recruiting trials for metastatic colorectal cancer are listed on ClinicalTrialsFinder across 6 cities in 47 countries. The largest study group is Phase 2 with 72 trials, with the heaviest enrollment activity in Houston, Shanghai, and Barcelona. Lead sponsors running metastatic colorectal cancer studies include Fudan University, M.D. Anderson Cancer Center, and Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

Browse metastatic colorectal cancer trials by phase

Treatments under study

About Metastatic Colorectal Cancer Clinical Trials

Looking for clinical trials for Metastatic Colorectal Cancer? There are currently 87 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Colorectal Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Colorectal Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 136 trials

Recruiting
Phase 3

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Metastatic Colorectal Cancer
EMD Serono Research & Development Institute, Inc.1,020 enrolled8 locationsNCT07549412
Recruiting
Phase 2

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
AbbVie390 enrolled51 locationsNCT06820463
Recruiting
Phase 3

Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment

Unresectable Metastatic Colorectal Cancer
University Hospital, Tours244 enrolled4 locationsNCT06642844
Recruiting
Phase 2

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Metastatic Breast CarcinomaMetastatic Ovarian CancerMetastatic Pancreatic Cancer+2 more
National Cancer Institute (NCI)332 enrolled1 locationNCT01174121
Recruiting
Phase 2

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

Colorectal, CancerCholangiocarcinomaColorectal Neoplasms+10 more
National Cancer Institute (NCI)70 enrolled1 locationNCT05286814
Recruiting
Phase 3

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Metastatic Colorectal Cancer
Amgen450 enrolled290 locationsNCT06252649
Recruiting
Phase 1

A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer
Hoffmann-La Roche180 enrolled1 locationNCT07416552
Recruiting
Phase 1Phase 2

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer
National Cancer Institute (NCI)60 enrolled1 locationNCT06149481
Recruiting
Phase 2

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

MCRCMSS Metastatic Colorectal CancerRas-mutated Metastatic Colorectal Cancer
Oncolytics Biotech60 enrolled3 locationsNCT07446322
Recruiting
Phase 1Phase 2

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

Advanced or Metastatic Colorectal Cancer
Janssen Research & Development, LLC225 enrolled53 locationsNCT05379595
Recruiting
Phase 1Phase 2

A Clinical Study of Arfolitixorin in Patients With mCRC

Metastatic Colorectal Cancer (Mcrc)
Isofol Medical AB90 enrolled3 locationsNCT06922383
Recruiting
Phase 1

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

First-line TreatmentMetastatic Colorectal Cancer (CRC)Phase 1+4 more
M.D. Anderson Cancer Center41 enrolled1 locationNCT07500298
Recruiting
Phase 1

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Non-small Cell Lung CancerNSCLCMetastatic Pancreatic Ductal Adenocarcinoma+11 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)665 enrolled17 locationsNCT06917079
Recruiting
Phase 2

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

Refractory Metastatic Colorectal Cancer
Delcath Systems Inc.90 enrolled14 locationsNCT06607458
Recruiting

Real World Multicenter National Study to Evaluate the Effectiveness and Safety of Biosimilar Bevacizumab Elovie

Metastatic Colorectal Cancer
Libbs Farmacêutica LTDA133 enrolled14 locationsNCT06808685
Recruiting
Phase 2Phase 3

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb990 enrolled286 locationsNCT07221357
Recruiting
Not Applicable

Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer (CRC)Antineoplastic Agents, ImmunologicalVEGFR-TKI
Federation Francophone de Cancerologie Digestive300 enrolled83 locationsNCT07124858
Recruiting

Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer

Metastatic Colorectal CancerBRAF V600E Mutation
Swiss Cancer Institute30 enrolled12 locationsNCT07617610
Recruiting
Phase 1

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Metastatic Colorectal Cancer
Hoffmann-La Roche542 enrolled82 locationsNCT04929223
Recruiting
Phase 2

Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
M.D. Anderson Cancer Center90 enrolled1 locationNCT06959550